Current advances in nanomedicine-based therapies for acute kidney injury DOI

Ruimiao Chang,

Xiangmeng Qu, Yuting Ye

и другие.

Chinese Chemical Letters, Год журнала: 2024, Номер unknown, С. 110802 - 110802

Опубликована: Дек. 1, 2024

Язык: Английский

Carbohydrate polymer-functionalized metal nanoparticles in cancer therapy: A review DOI
Xi Zhou, Dongbin Zhang, Mingming Han

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер 306, С. 141235 - 141235

Опубликована: Фев. 21, 2025

Язык: Английский

Процитировано

0

Chitosan Nanoparticle Encapsulation of Thymus Capitatus Essential Oil: In Vitro Release, Antioxidant, Antibacterial Activity and Cytotoxicity in MDA-MB-231 Cells DOI
Huseyin Beyaz, Doğa Kavaz, Nahit Rizaner

и другие.

Pharmaceutical Development and Technology, Год журнала: 2025, Номер unknown, С. 1 - 50

Опубликована: Март 31, 2025

Thymus capitatus (Th. Ca) is known to treat mouth ulcers and respiratory infections in Cyprus. However, antioxidant, antibacterial cytotoxic potential of Th. Ca. EO on MDA-MB-231 cells its' encapsulation into nanoparticles has not been well studied. Therefore, we aimed analyse the antibacterial, potential, loading efficiency vitro release profile both Chitosan Nanoparticle (Ch. Np) - EO. GC-MS analysis revealed 53.97% carvacrol, 14.53% borneol 12.09% sabinene presence The Ch. Np. was calculated as 35.27% reached a maximum 68% pH 7 for two weeks. Minimum Inhibitory Concentration (MIC) assay showed that E. coli had an MIC50 0.3215 mg/ml while B. subtilis 0.5304 mg/ml. antioxidant activity assessed by performing DPPH with IC50 = 440 μg/ml. Trypan Blue Assay 60 µg/ml significantly reduced cell viability 10.7% at 48h 20.06% 72h. Overall, shown promising formulation pharmaceutical industry.

Язык: Английский

Процитировано

0

Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics DOI Creative Commons
Amelia Ultimo, Ayushi Jain, Elisabet Gómez-González

и другие.

Molecular Pharmaceutics, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

Antiangiogenic medications for cancer treatment have generally failed in showing substantial benefits terms of prolonging life on their own; effects are noticeable only when combined with chemotherapy. Moreover, treatments based prolonged antiangiogenics administration demonstrated to be ineffective stopping tumor progression. In this scenario, nanotherapeutics can address certain issues linked existing antiangiogenic treatments. More specifically, they provide the ability target tumor's blood vessels enhance drug accumulation and manage release, ultimately decreasing undesired side effects. Additionally, enable multiple angiogenesis inhibitors at same time as Key reports field include design polymeric nanoparticles, inorganic vesicles, hydrogels loading substances like endostatin interleukin-12. Furthermore, nanoformulations been proposed efficiently control relevant pro-angiogenic pathways such VEGF, Tie2/Angiopoietin-1, HIF-1α/HIF-2α, TGF-β, providing powerful approaches block growth metastasis. article, we outline a selection that developed past ten years.

Язык: Английский

Процитировано

0

Chitosan nanovectors for siRNA delivery: New horizons for nonviral gene therapy DOI
Mahdi Rahimi, Zahra Kariminezhad,

Elsa-Patricia Rondon

и другие.

Carbohydrate Polymers, Год журнала: 2025, Номер unknown, С. 123581 - 123581

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Current advances in nanomedicine-based therapies for acute kidney injury DOI

Ruimiao Chang,

Xiangmeng Qu, Yuting Ye

и другие.

Chinese Chemical Letters, Год журнала: 2024, Номер unknown, С. 110802 - 110802

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

0